Part 2/7:
The company’s latest earnings report revealed that revenues were lighter than expected, with profits taking a downturn. Despite the increase in the dividend, overall financial health appears strained as the company navigates a post-hype period for its flagship hepatitis C drugs. Historically, Gilead’s success was driven by these medications, which generated billions of dollars. However, recent results show that the revenue from these drugs has stagnated and, in some cases, declined.